Budget impact analysis of medicines: updated systematic review and implications.
about
Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications.Evidence on the cost-effectiveness of lifelong antiretroviral therapy for prevention of mother-to-child transmission of HIV: implications for resource-limited countries in sub-Saharan Africa.Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis.Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions.Evaluating the Treatment Costs for Uncomplicated Malaria at a Public Healthcare Facility in Nigeria and the Implications.The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA).
P2860
Budget impact analysis of medicines: updated systematic review and implications.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Budget impact analysis of medicines: updated systematic review and implications.
@en
type
label
Budget impact analysis of medicines: updated systematic review and implications.
@en
prefLabel
Budget impact analysis of medicines: updated systematic review and implications.
@en
P2093
P2860
P1476
Budget impact analysis of medicines: updated systematic review and implications.
@en
P2093
Alessandra Maciel Almeida
Augusto A Guerra Júnior
Daniel Resende Faleiros
Eli Iola Gurgel Andrade
Francisco A Acurcio
Juliana Álvares
Vânia Eloisa de Araújo
P2860
P304
P356
10.1586/14737167.2016.1159958
P50
P577
2016-02-27T00:00:00Z